-
-
-
-
-
-
-
Verastem Oncology names new chairman, president of development
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
BTIG on Verastem (VSTM): '2H25 Top Pick'
-
-
-
-
-
-
-
Verastem Oncology (VSTM) Misses Q1 EPS by 79c
-
-
-
-
-
-
-
Verastem (VSTM) PT Raised to $14 at Guggenheim
-
-
-
-
-
-
-
Verastem Oncology (VSTM) Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

